Sanofi Shines, Bayer Brighter, AZ Loses Leadership: China Roundup
This article was originally published in PharmAsia News
Multinational pharmaceutical players in China are recovering in the aftermath of a drastic slowdown in the country, growing on average by 4% in the last quarter, although one leading company quadrupled that figure. PharmAsia News has combed through earnings reports to bring you the winners, laggards and most successful strategies among major global firms in China.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
With gene editing making the news again after the recent Nobel Prize for CRISPR, China’s EdiGene has been raising new funds to accelerate its pipeline to the clinic, led by a potential one-time cure for thalassemia and helped by recent regulatory changes.